Welcome to Bold Profits Daily!
Today, I am beyond excited to tell you about an incredible reawakening going on in the market right now. I call this a reawakening because this rally is in a forgotten sector that many investors have given up on.
However, the big-money investors are aware of the phenomenal opportunities in this sector, and they’re dying to buy a part of it.
A Massive Rally Is Brewing
The sector I’m talking about is biotech.
See, there’s been a lot of behind-the-scenes movement going on in the market for the last few months, which tells me that there’s a massive rally brewing in biotech. And right now, I can see that the vast majority of Main Street investors are ignoring these four glaring signs of an upcoming boom.
These indicators tell me one critical thing: Big-money investors want to play in biotech. And we’re going to beat them to it.
In today’s Bold Profits Daily, I talk about what these four indicators are, and why you should get in now so that you can profit off this rocketing sector.
Check out the video below:
Hi there, it’s Paul, and this is your very first — for me, at least — edition of Bold Profits Daily.
This week, I want to tell you about an incredible opportunity in a sector that people have given up for dead. And because of that, they’re missing signs that this incredibly hot sector is about to take off.
I can tell you from past history that when this sector takes off, people make big money fast. So this is a really, really exciting opportunity.
So, what am I talking about? The sector I’m talking about is biotechnology. Those of you who can think back to 2013, 2014 and 2015 — this was an incredibly hot sector.
There were stocks that made people hundreds of percent — in some cases, even thousands of percent!
There have been things that’s been going on for the last few months that’s telling me that the insiders have been nibbling and accumulating biotech stocks — big and small — pushing things up ever so slowly so most of you won’t notice.
And, it’s all now suddenly coming out into the open. You might’ve heard that just this week, Bristol Myers has agreed to buy another large biotech company called, Celgene for $74 billion. If you were in Celgene, you made 30% overnight — just like that.
That’s a good deal, people that own Bristol Myers are going to do well because I believe that Bristol Myers’ stock is actually going to benefit from this deal.
Another deal that happened earlier in December, was when another large pharmaceutical company, GlaxoSmithKline Smith bought a biotech called Tesaro, for $4 billion. In that case, Tesaro’s shares rocketed up by 70% — again, rocket-fast, in a day.
There’s also other small details that are really important for you to know. Even though there’s been this fear and panic in the stock market, biotech [stocks] have actually been doing OK.
And, I measure that by the fact that Wall Street has been able to sell 51 IPOs to investors while all this panic and gloom has been going on, including one mega deal for a company called Moderna, where they did it for $600 million!
In other words, the big money wants to play in biotech!
The deal between Bristol Myers and Celgene tells you that. The deal between GlaxoSmithKline and Tesaro tells you that. The deal 51 IPOs tells you that. The deal from Moderna tells you that.
That means, it’s time for you to get into biotech right now. And, the easiest way to get into biotech is to own an ETF.
You can choose between any number of biotech exchange-traded funds (ETFs). However, I am going to show you a very unique ETF that will give you more exposure to names like Tesaro that can rocket up if somebody buys them.
It can rocket up if they have a good result in one of their clinical trials, or there is an announcement in one of their drugs, or even a company that has a similar drug.
The ticker symbol for that ETF is the SPDR S&P Biotech ETF (NYSE: XBI). This is the Nasdaq biotechnology ETF. And the secret sauce that makes this ETF move more than others is because it has an equal-weighted strategy.
In other words, it puts equal-weights into all of the companies. That’s different from other ETFs, which base it off the stock market value. In other words, the bigger companies get bigger weights, and the smaller companies get really small weights.
Obviously, if you’re equal-weighted, if a small company goes up a lot, that ETF is going to jump higher. So it’s XBI, which is the Nasdaq biotech ETF.
Now, this is obviously a shameless plug. Nonetheless, if you really want the single names that can shoot higher 300% … 500% … 700% … even 1000% like they did in the last bull market, you should look at the stocks we have in one of my services, Extreme Fortunes. There, we pick the really small biotech stocks that can rocket higher.
So, that’s my Bold Profits Daily for you this week. Buy into biotech right now using SPDR S&P Biotech (NYSEARCA: XBI), which is the ticker symbol for the ETF that I would tell you to buy into to get in on the coming bull market in biotech.
Also, check out my Extreme Fortunes service, where we have a lot of stocks that are very small, and read to go up a lot in the biotech sector.
I’ll have another Bold Profits Daily video for you next week. Until then, this is Paul saying bye.
Ride the Biotech Bull Market to Enormous Profits
If you’re a member of my Extreme Fortunes service, then you’re well aware that some of our best-performing stocks are in biotech. This sector plays a huge role in my service because it’s the small biotech stocks that can really rocket higher.
However, if you’re not a member of Extreme Fortunes and are looking for a way to participate in this biotech boom, the SPDR S&P Biotech ETF (NYSE: XBI) is the next best thing.
This particular exchange-traded fund (ETF) is one of the best ways for you to get exposure to the benefits of biotech, as it uses an equal-weighted strategy.
That means XBI puts an equal weight on all of the tiny but innovative biotech companies — not just the famous giants. So, if a small company goes up a lot, the ETF is going to soar even higher.
That’s all I have for this week. However, I’ll be back next week with another Bold Profits Daily.
Editor, Profits Unlimited